Cordella Pulmonary Artery Sensor System (CorPASS)
Endotronix, Inc. · Decision date Jun 20, 2024
What did the FDA approve?
Endotronix, Inc. received an original PMA approval (P230040) on 2024-06-20 for the Cordella Pulmonary Artery Sensor System, an implantable hemodynamic device under product code MOM. The source statement describes the system as intended to measure, record and transmit pulmonary artery pressure data from NYHA Class III heart failure patients at home on diuretics and guideline-directed medical therapy who have been stable for 30 days on GDMT. The stated output purpose is to aid clinicians in assessment and management of heart failure, with the goal of reducing heart failure hospitalizations.
No supplement type or reason is recorded, so the supplied record identifies this as an original PMA rather than a change to an earlier approval; the identifier does not establish a parent PMA. The statement reports an intended purpose and a stated goal, not independent evidence of safety or clinical effectiveness, and the record supplies no performance or trial data. Class III status, diuretic use, GDMT stability of 30 days, and the hospitalization-reduction goal are the stated scope boundaries.
FDA approval order statement
The Cordella Pulmonary Artery Sensor System is intended to measure, record and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients who are at home on diuretics and guideline-directed medical therapy (GDMT) as well as have been stable for 30 days on GDMT. The device output is meant to aid clinicians in the assessment and management of heart failure, with the goal of reducing heart failure hospitalizations.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Jun 20, 2024
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P230040
- Regulatory pathway
- Premarket approval application
- Applicant
- Endotronix, Inc.
- Product code
- MOM
- Decision code
- APPR
- Decision date
- Jun 20, 2024
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, hemodynamic, implantable.
- Applicant
- Endotronix, Inc.
- Product code
- MOM
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P230040 received
Application receipt date recorded by FDA.
P230040 · FDA decision
APPR
P230040/S033 · Related supplement
Cordella Pulmonary Artery Sensor System (CorPASS)
P230040/S034 · Related supplement
Cordella Pulmonary Artery Sensor System (CorPASS)
P230040/S031 · Related supplement
Cordelia Pulmonary Artery Pressure Sensor System (CorPASS)
P230040/S035 · Related supplement
Cordella Pulmonary Artery Sensor System (CorPASS)
P230040/S030 · Related supplement
Cordella Pulmonary Artery Sensor System
Timeline entries are records held by MedtechLedger for P230040. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230040
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Endotronix, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Endotronix, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
| Endotronix, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Endotronix, Inc. | PMA supplement | Oct 20, 2026 | FDA | |
Cordella Pulmonary Artery Sensor SystemP230040/S030 | Endotronix, Inc. | PMA supplement | Oct 29, 2026 | FDA |
Explore the linked device profile
Other records with product code MOM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Sep 30, 2026 | FDA | |
CardioMEMS PA Sensor and Delivery SystemP100045/S093 | ABBOTT MEDICAL | PMA supplement | Sep 30, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Sep 11, 2026 | FDA | |
| ABBOTT MEDICAL | PMA approval | May 28, 2014 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Endotronix, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1415 W. Diehl Rd., Suite 500w, Naperville, IL, 60563
Sources and methodology
- Original FDA record: P230040
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




